Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Allergy Therapeutics ( (GB:AGY) ) just unveiled an update.
Allergy Therapeutics has secured shareholder approval at its general meeting to allot up to 610 million new ordinary shares, representing around 10% of its existing share capital, and to disapply pre-emption rights, giving the board flexibility to conduct a non-pre-emptive equity raise via private placements if it chooses to proceed. While no terms, investors or pricing have yet been agreed and there is no certainty a fundraise will occur, any proceeds would support the company’s strategy to advance treatments for grass and peanut allergies, bolster working capital, and prepare for a planned dual listing in Hong Kong; the company also confirmed it has posted its annual report for the year to 30 June 2025 and made it available on its website.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, which poses significant risks. Despite strong technical indicators suggesting bullish momentum, the overbought condition may lead to a correction. The negative P/E ratio and lack of dividend yield further detract from the stock’s attractiveness.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is a UK-headquartered international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including aluminium-free allergy immunotherapies with potential disease-modifying effects. The group markets proprietary and third-party allergy products through subsidiaries in nine major European countries and via distribution agreements in a further ten countries, targeting patients with conditions such as grass and peanut allergies.
Average Trading Volume: 413,620
Technical Sentiment Signal: Buy
Current Market Cap: £690.9M
See more insights into AGY stock on TipRanks’ Stock Analysis page.